公开(公告)号：US08642305B2

公开(公告)日：2014-02-04

申请号：US13676879

申请日：2012-11-14

Applicant: Chr. Hansen A/S

Inventor： Inge Knap ,  Ane Knarreborg ,  Thomas Dyrmann Leser ,  Bente Lund

IPC: C12P1/04

CPC classification number: C12N1/20 ,  A23K10/18 ,  A23K50/30 ,  A23K50/75 ,  A23K50/80 ,  A23L27/203 ,  C12N15/01 ,  C12R1/125

Abstract: A bacillus composition characterized by fast germination and outgrowth in bile salts (simulated gut environment) and by high-level secretion of phytase. The bacillus composition may be used as supplement in animal feed where it has a probiotic (health promoting) effect and increases the digestion and availability of nutrients from animal feeds.

Abstract translation: 一种芽孢杆菌组合物，其特征在于胆汁盐（模拟肠道环境）的快速发芽和生长以及植酸酶的高水平分泌。 芽孢杆菌组合物可以用作动物饲料中的补充物，其中它具有益生菌（促进健康）作用并且增加动物饲料中营养物质的消化和可利用性。

公开(公告)号：US10022408B2

公开(公告)日：2018-07-17

申请号：US15504913

申请日：2015-08-28

Applicant: CHR. HANSEN A/S

Inventor： Thomas Dyrmann Leser ,  Dorte Myling-Petersen ,  Jeffrey Earl Christensen ,  Anja Wellejus ,  Elke Brockmann

IPC: A01N63/00 ,  A61K35/745 ,  A61K47/26 ,  C12R1/01

Abstract: The present invention relates to novel isolated strains of Bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (TER) of a Caco-2 cell monolayer after 10 h treatment to more than 120% of TER at treatment start, ii) inducing secretion of >200 pg/ml of IL-10, and/or iii) inducing an IL-10:IL-12 ratio >1 when co-incubated with human PBMC derived dendritic cells. The strains may have one, two or all three of these capabilities. The present invention relates to the use of these novel strains for the in prevention, alleviation of symptoms, and treatment of diseases or conditions with an underlying impaired intestinal barrier function and pro-inflammatory activation of the mucosa. More specifically, the present invention relates to se of an isolated strain according to the invention for the prevention, alleviation of symptoms, or treatment of intestinal inflammatory conditions such as IBD and IBS, liver diseases such as NAFLD, NASH, cirrhosis, and alcohol-related liver disease, metabolic disorders such as metabolic syndrome, insulin resistance, type 2 diabetes, obesity, cardiovascular atherosclerosis, autoimmune diseases, such as celiac disease, type 1 diabetes, multiple sclerosis and rheumatoid arthritis, and mental conditions such as major depressive disorders, a mood disorder, a cognitive chronic fatigue syndrome, and anxiety.

公开(公告)号：US20130336942A1

公开(公告)日：2013-12-19

申请号：US13900243

申请日：2013-05-22

Applicant: CHR-HANSEN A/S

Inventor： Thomas Dyrmann Leser ,  Thomas GUNNARSSON ,  Jens KILDSGAARD ,  Janni Wandahl PEDERSEN ,  Bénédicte FLAMBARD

IPC: A61K35/74 ,  A61K45/06

CPC classification number: A61K35/742 ,  A61K8/99 ,  A61K31/702 ,  A61K35/747 ,  A61K45/06 ,  A61Q19/06 ,  C12R1/225

Abstract: The use of probiotic bacteria that modulate expression of a number of satiety markers in the intestine and reduces fat deposition to promote an optimal body weight of a mammal is described. The invention further relates to a composition comprising such a probiotic strain of bacteria and/or a fraction of said strain and/or metabolite of said strain for the preparation of a composition for administration to a mammal for promoting an optimal body weight of a mammal.

Abstract translation: 描述了使用调节许多饱腹感标记物在肠中的表达并减少脂肪沉积以促进哺乳动物的最佳体重的益生菌。 本发明还涉及一种组合物，其包含这样的益生菌菌株和/或所述菌株的所述菌株和/或代谢物的级分，用于制备用于给哺乳动物施用哺乳动物的最佳体重的组合物。